BioSpace News Archive

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of February 2023, which is payable on March 15, 2023 to shareholders of record at the close of business on February 28, 2023.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced updates on progress in the pre-clinical development program for long-acting PAS-nomacopan as a potential treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).

Aprea Therapeutics, Inc. (Nasdaq: APRE), today announced that it received an award notification from the National Cancer Institute (NCI) for the development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer (HGSOC).

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, provided a business update with respect to its wholly-owned contract manufacturing subsidiary, Pharmaloz Manufacturing, Inc..

Sotera Health Company announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2022 before the market opens on Tuesday, February 28, 2023.

Xilis and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to deploy Xilis’s proprietary MicroOrganoSphere™ (MOS) technology in support of preclinical research to accelerate the development of novel cancer therapies.

Elevance Health (NYSE: ELV) today announced the closing of its acquisition of BioPlus, a comprehensive specialty pharmacy subsidiary of CarepathRx, a portfolio company of Nautic Partners.

Mercy BioAnalytics, Inc. announced that Dawn Mattoon, PhD, has assumed the role of Chief Executive Officer and a member of the company’s Board of Directors, transitioning from her prior role as Chief Operating Officer as part of the company’s succession planning.